Etoricoxib in Patients With Parkinsonian Disease

NCT07370532 | Recruiting Phase 2

• 1 other identifier: 98658
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (1)

• - Change in The Unified Parkinson's Disease Rating Scale

  \- Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

  6 months

Study Arms (2)

Control group

ACTIVE COMPARATOR

(levo-dopa group, n =30) who will receive levo-dopa/carbidopa (125/12.5) mg three times daily for 6 months.

Drug: L-dopa

Etoricoxib group

ACTIVE COMPARATOR

will receive levo-dopa/carbidopa (125/12.5) mg three times daily plus Etoricoxib 90 mg once daily

Drug: L-dopa; Drug: Etoricoxib

Interventions

L-dopa DRUG

Levodopa is the standard therapy in PD.

Control group; Etoricoxib group

Etoricoxib DRUG

Etoricoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1) and by the inducible COX-2 enzymes and are secreted mainly by astrocytes and microglia.

Etoricoxib group

Eligibility Criteria

• Age: 50 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years.
• Both male and female will be included.
• Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

You may not qualify if:

• Breast feeding
• Patients with significant liver and kidney function abnormalities.
• Alcohol and / or drug abusers.
• Patients with known allergy to the study medications
• Pregnant women and women with planned pregnancy.
• Patients who are currently using other anti-inflammatory drugs.

Sponsors & Collaborators

• Ihab Elsayed Hassan: lead

Study Sites (1)

Mansoura University

Al Mansurah, 26548, Egypt

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Interventions

Levodopa; Etoricoxib

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Dihydroxyphenylalanine; Catecholamines; Amines; Organic Chemicals; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Phenylalanine; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids; Amino Acids, Peptides, and Proteins; Tyrosine; Sulfones; Sulfur Compounds; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Lecturer

Study Record Dates

• First Submitted: January 17, 2026
• First Posted: January 27, 2026
• Study Start: January 30, 2026
• Primary Completion (Estimated): November 10, 2027
• Study Completion (Estimated): November 20, 2027
• Last Updated: April 8, 2026

Record last verified: 2026-04

Locations

EG (1)